Bayer (BAYN) Given “Buy” Rating at JPMorgan Chase & Co.
Bayer (FRA:BAYN)‘s stock had its “buy” rating restated by research analysts at JPMorgan Chase & Co. in a research note issued on Wednesday.
A number of other research analysts also recently weighed in on the company. Kepler Capital Markets set a €83.00 ($96.51) price target on Bayer and gave the company a “neutral” rating in a report on Wednesday. Warburg Research set a €85.00 ($98.84) price target on Bayer and gave the company a “neutral” rating in a report on Wednesday. UBS Group set a €130.00 ($151.16) target price on Bayer and gave the company a “buy” rating in a research note on Wednesday. Deutsche Bank set a €130.00 ($151.16) target price on Bayer and gave the company a “buy” rating in a research note on Monday. Finally, Commerzbank set a €111.00 ($129.07) target price on Bayer and gave the company a “buy” rating in a research note on Monday. Nine equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Bayer currently has a consensus rating of “Buy” and an average target price of €106.09 ($123.36).
Shares of BAYN stock opened at €78.09 ($90.80) on Wednesday. Bayer has a 1-year low of €91.58 ($106.49) and a 1-year high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
See Also: Investing in Growth Stocks
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.